

Total costs	1999–2002, 2007–08, 2009–10, 2011–12 complete set	1999–2002, 2007–08, 2009–10, 2011–12 partial set	NHANES III complete set
Materials and Equipment—contractor: Plates, reagents, assays, aliquoting and packaging samples; use of equipment .....	\$1.51	\$4.53	\$0.75
Labor—contractor: Processing, handling, and shipping; NCHS: Data quality control .....	4.98	24.90	2.49
Proposal review and Administrative expenses—contractor: Inventory management and reporting; NCHS: Management of proposal process non-NCHS: Technical panel fees .....	3.02	6.04	1.51
Space—contractor: Freezer use and maintenance .....	5.59	5.59	2.79
Cost per sample .....	15.10	41.06	7.55
Cost per new proposal:			
1999–2002 .....	118,369	*	.....
2007–2008 .....	69,641	.....	.....
2009–2010 .....	73,884	.....	.....
2011–2012 .....	62,605	.....	54,050
III .....	.....	.....	.....
Cost per additional proposal:**			
1999–2002 .....	5,918	***	.....
2007–2008 .....	3,633	.....	.....
2009–2010 .....	3,694	.....	.....
2011–2012 .....	3,131	.....	2,702
III .....	.....	.....	.....

\* Cost calculated upon request.  
 \*\* Additional research using DNA samples already obtained from previous solicitations.  
 \*\*\* This charge will be 5 percent of the original cost.

**Note:** Applicable CDC overhead and NCHS management and oversight charges will be added to these rates for proposals coming from Federal agencies.

Dated: February 14, 2019.

**Sandra Cashman,**  
*Executive Secretary, Centers for Disease Control and Prevention.*

[FR Doc. 2019–02908 Filed 2–20–19; 8:45 am]  
 BILLING CODE 4163–18–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Disease, Disability, and Injury Prevention and

Control Special Emphasis Panel (SEP)—RFA—CE–19–005, Research Grants for Preventing Violence and Violence Related Injury.

*Date:* May 14–15, 2019.

*Time:* 8:30 a.m.–5:30 p.m., EDT.

*Place:* Atlanta Marriott Buckhead and Conference Center, 3405 Lenox Road NE, Atlanta, GA 30326.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Mikel Walters, Ph.D., Scientific Review Official, NCIPC, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone (404) 639–0913, *MWalters@cdc.gov*.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Sherri Berger,**  
*Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2019–02949 Filed 2–20–19; 8:45 am]  
 BILLING CODE 4163–18–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—IP19–001, Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections Among Native Americans/Alaskan Natives; IP19–002, Increasing Influenza and Tdap Vaccination of Pregnant Women in Obstetric/Gynecologic Practices in Large Health Systems Through Quality Improvement Interventions and IP19–003, Understanding and Improving Immunization Services Among Adult Hospital Inpatient and Observation/ Clinical Decision Unit Settings; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—IP19–001, Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections Among Native Americans/Alaskan Natives; IP19–002, Increasing Influenza and Tdap Vaccination of Pregnant Women in Obstetric/Gynecologic Practices in Large Health Systems through Quality Improvement Interventions and IP19–003, Understanding and Improving Immunization Services Among Adult Hospital Inpatient and Observation/ Clinical Decision Unit Settings; March 19–20, 2019; 10:00 a.m.–5:00 p.m.,